Logo

Ubix Therapeutics Collaborates with Yuhan to Develop UBX-103 for Treating Metastatic Castration Resistant Prostate Cancer

Share this
Ubix Therapeutics

Ubix Therapeutics Collaborates with Yuhan to Develop UBX-103 for Treating Metastatic Castration Resistant Prostate Cancer

Shots:

  • Ubix & Yuhan have signed an exclusive license agreement for the development & commercialization of UBX-103 to treat mCRPC
  • As per the agreement, Yuhan gains UBX-103’s exclusive global rights to carry out preclinical & clinical studies plus commercialization. Ubix is entitled to receive $3.6M upfront, ~$105M development, regulatory & commercial milestones along with high single-digit royalty. It will receive profit sharing on sublicensing to a 3rd party
  • Additionally, UBX-103 showed AR degradation with picomolar DC50, effectiveness against treatment-induced resistance mutations and tumor growth inhibition that are resistant to next-gen. hormonal therapy in the in vivo preclinical model

Ref: Ubix Therapeutics | Image: Ubix Therapeutics

Related News:- Laekna’s LAE002(Afuresertib) + LAE001 Receives FDA Approval for P-III Trial Protocol to Treat Prostate Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions